Molecular Evaluation of BH3-mimics Inhibitor of Bladder Cancer as Targiting Chemotherapy(Review article)

Elmoghazy, Eman Ibrahim; Zakaria, Mahmoud; Abu Almaaty, Ali Hussein; Hassan, Mohamed Kamel

doi:10.21608/ajbas.2023.242423.1192

Molecular Evaluation of BH3-mimics Inhibitor of Bladder Cancer as Targiting Chemotherapy(Review article)

Document Type : Review Article

Authors

¹ Zoology Department, Faculty of Science, Port Said University, Port Said, Egypt

² Genomic Unit, Urology & Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt

³ Zoology Department, Faculty of Science, Port Said University

⁴ Faculty of Science, Port Said University, Appointed visiting professor at the Center for Genomics, Zewail City for Science and Technology

10.21608/ajbas.2023.242423.1192

Abstract

In Egypt, bladder cancer (BC) is considered the fourth most prevalent type of cancer. Bladder cancer is acknowledged as the seventh cause of mortality due to cancer among men. Researchers identified three different types of BC: squamous cell carcinoma (SCC), urothelial carcinoma (UC), and transitional cell carcinoma (TCC). BC accounts for around 31% of all cancer cases between Egyptian, making it a common form of cancer. Many research investigations have shown a relationship between BC incidence and schistosomiasis prevalence in endemic areas. This relationship includes SCC as well as UC, which is why this cancer is called schistosomal or bilharzial BC. A crucial element of the pro-apoptotic action is the BH3 domain. A class of compounds known as BH3 mimetic compounds has antagonistic effects of the BCL-2 family members, with anti-apoptotic effect, hence inducing apoptosis in cancer cells. Many BH3 mimics have been identified recently, and an increasing amount of research is showing how well they work to treat cancer.Evaluate the effect of BH3 mimics as inhibitor for targeting cancer specially bladder cancer. A thorough evaluation of relevant literature was done for the current investigation.

Keywords